{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:33:12Z","timestamp":1775233992538,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>The majority of patients with androgen-dependent prostate cancer (PCa) develop resistance to hormone therapy after approximately 18\u201324\u00a0months of androgen deprivation therapy treatment. During this process, PCa cells progressively lose their sensitivity to androgens and evolve into castration-resistant prostate cancer leading to uncontrolled tumor growth and ultimately the failure of endocrine therapy. To develop potential anti-prostate cancer agents, in this study, we identified a novel ether-type arylpiperazine derivative as a potent androgen receptor (AR) antagonist, uncovering a series of effective antiproliferative compounds. The derivatives (<jats:bold>7, 11, 17, 19, 20, 21, 22, 23<\/jats:bold>, and <jats:bold>24<\/jats:bold>) demonstrated strong cytotoxicity against cancer cells, with <jats:bold>17, 19, 20<\/jats:bold>, and <jats:bold>23<\/jats:bold> showing significant androgen receptor antagonistic activity (Inhibition% &amp;gt;60) and robust AR binding affinities. The structure-activity relationship (SAR) of these developed derivatives was discussed based on data. Docking study suggested that the compound <jats:bold>19<\/jats:bold> mainly bind to AR ligand binding pocket site through Van der Waals\u2019 force interactions. This research presents a promising lead compound for developing anticancer agents targeting prostate cancer therapy.<\/jats:p>","DOI":"10.3389\/fchem.2025.1557275","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:18:24Z","timestamp":1743149904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Synthesis, bioactivity, and molecular docking studies: novel arylpiperazine derivatives as potential new-resistant AR antagonists"],"prefix":"10.3389","volume":"13","author":[{"given":"Hua","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haowei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1021\/jm200532b","article-title":"Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening","volume":"54","author":"Axerio-Cilies","year":"2011","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.3390\/cancers15184653","article-title":"Nuclear estrogen receptors in prostate cancer: from genes to function","volume":"15","author":"Belluti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0226057","DOI":"10.1371\/journal.pone.0226057","article-title":"Estrogen receptor \u03b2 exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity","volume":"15","author":"Chaurasiya","year":"2020","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"53475","DOI":"10.1021\/acsami.2c14570","article-title":"Co-Assembled Nanocarriers of de novo Thiol-Activated hydrogen sulfide Donors with an RGDFF Pentapeptide for targeted therapy of non-small-cell Lung cancer","volume":"14","author":"Chen","year":"2022","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B5","doi-asserted-by":"publisher","first-page":"134740","DOI":"10.1016\/j.snb.2023.134740","article-title":"A stable NIR fluorescent probe for imaging lipid droplets in triple-negative breast cancer","volume":"398","author":"Chen","year":"2023","journal-title":"Sens. Actuat B-Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.steroids.2018.02.002","article-title":"Synthesis and biological evaluation of estrone 3-O-ether derivatives containing the piperazine moiety","volume":"134","author":"Chen","year":"2018","journal-title":"Steroids"},{"key":"B7","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.3390\/molecules190812048","article-title":"Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines","volume":"19","author":"Chen","year":"2014","journal-title":"Molecules"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.bmcl.2018.03.070","article-title":"Synthesis, biological evaluation and SAR of naftopidil-based arylpiperazine derivatives","volume":"28","author":"Chen","year":"2018","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3390\/molecules22111857","article-title":"Synthesis and antitumor activity of novel arylpiperazine derivatives containing the Saccharin moiety","volume":"22","author":"Chen","year":"2017","journal-title":"Molecules"},{"key":"B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bmcl.2014.11.049","article-title":"Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines","volume":"25","author":"Chen","year":"2015","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bmc.2018.11.029","article-title":"Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents","volume":"27","author":"Chen","year":"2019","journal-title":"Bioorg Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bmc.2019.115081","article-title":"Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety","volume":"27","author":"Chen","year":"2019","journal-title":"Bioorg Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2423643","DOI":"10.1002\/adfm.202423643","article-title":"Quantum dots\u2010Engineered Flexible Hydrogel as Plant\u2010Wearable sensor for on\u2010site Profiling Dynamic Pesticide Degradation","author":"Chen","year":"2025","journal-title":"Adv. Funct. Mater"},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/rru.s303215","article-title":"Evolution of androgen deprivation therapy (ADT) and its new Emerging Modalities in prostate cancer: an Update for Practicing Urologists, Clinicians and Medical Providers","volume":"14","author":"Choi","year":"2022","journal-title":"Res. Rep. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/jco.23.00433","article-title":"Targeting the androgen signaling Axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"215619","DOI":"10.1016\/j.canlet.2022.215619","article-title":"Molecular mechanisms and genetic alterations in prostate cancer: from diagnosis to targeted therapy","volume":"534","author":"Fontana","year":"2022","journal-title":"Cancer Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41388-020-01598-0","article-title":"Loss and revival of androgen receptor signaling in advanced prostate cancer","volume":"40","author":"Formaggio","year":"2021","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"129496","DOI":"10.1016\/j.snb.2021.129496","article-title":"Renovated multifunctional colorimetric\/fluorometric sensor for simultaneous detection, imaging of pH variance and antimicrobial therapies","volume":"332","author":"He","year":"2021","journal-title":"Sens. Actuat B-Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00432-017-2536-x","article-title":"Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells","volume":"144","author":"Ishii","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00432-017-2367-9","article-title":"Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells","volume":"143","author":"Iwamoto","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2174\/0113862073324077240624094140","article-title":"CircDUSP22 Attenuates the Ferroptosis of prostate cancer cells via miR-18a-5p\/SLC7A11\/GPX4 signaling","volume":"27","author":"Jiang","year":"2024","journal-title":"Comb. Chem. High. Throughput Screen"},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1248\/cpb.53.402","article-title":"N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists","volume":"53","author":"Kinoyama","year":"2005","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1248\/cpb.52.1330","article-title":"Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists","volume":"52","author":"Kinoyama","year":"2004","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1021\/jm201098n","article-title":"Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening","volume":"54","author":"Lack","year":"2011","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fendo.2020.00184","article-title":"Estrogen receptors promote Migration, Invasion and Colony formation of the androgen-independent prostate cancer cells PC-3 through \u03b2-Catenin pathway","volume":"11","author":"Lombardi","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41391-020-0217-3","article-title":"Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations","volume":"23","author":"Lu","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/iju.14667","article-title":"Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: a randomized controlled trial of silodosin versus naftopidil","volume":"28","author":"Maesaka","year":"2021","journal-title":"Int. J. Urol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"581515","DOI":"10.3389\/fonc.2020.581515","article-title":"Recent Discoveries in the androgen receptor pathway in castration-resistant prostate cancer","volume":"10","author":"Obinata","year":"2020","journal-title":"Front. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"947065","DOI":"10.3389\/fchem.2022.947065","article-title":"Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists","volume":"10","author":"Qi","year":"2022","journal-title":"Front. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1053675","DOI":"10.3389\/fchem.2022.1053675","article-title":"Synthesis, biological evaluation, and molecular docking of novel hydroxyzine derivatives as potential AR antagonists","volume":"10","author":"Qi","year":"2022","journal-title":"Front. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1021\/jm101163m","article-title":"Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies","volume":"54","author":"Sarswat","year":"2011","journal-title":"J. Med. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/or.2023.8530","article-title":"Estrogen receptors regulate galectin-3 in androgen-independent DU-145 prostate cancer cells","volume":"49","author":"Souza","year":"2023","journal-title":"Oncol. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"56132","DOI":"10.1021\/acsami.2c17889","article-title":"Chromatographic Separation of Aromatic amine Isomers: a solved issue by a new Amphiphilic pillar[6]arene stationary phase","volume":"14","author":"Sun","year":"2022","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B38","doi-asserted-by":"publisher","first-page":"127098","DOI":"10.1016\/j.talanta.2024.127098","article-title":"Separation performances of extended pillar[6]arenes, a new stationary phase for gas chromatography","volume":"283","author":"Sun","year":"2025","journal-title":"Talanta"},{"key":"B39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and prevalence of castration-resistant prostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat. Genet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.surfin.2023.102996","article-title":"AIE donor-dependent photosensitizer for enhance photodynamic antibacterial interface","volume":"39","author":"Xue","year":"2023","journal-title":"Surf. Interfaces"},{"key":"B42","doi-asserted-by":"publisher","first-page":"106117","DOI":"10.1016\/j.jsbmb.2022.106117","article-title":"Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia","volume":"221","author":"Zhan","year":"2022","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e102506","DOI":"10.1371\/journal.pone.0102506","article-title":"Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B45","doi-asserted-by":"publisher","first-page":"103662","DOI":"10.1016\/j.surfin.2023.103662","article-title":"Carbon quantum dots derived from resveratrol enhances anti-virulence activity against Pseudomonas aeruginosa","volume":"44","author":"Zhou","year":"2024","journal-title":"Surf. Interfaces"}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1557275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T08:18:27Z","timestamp":1743149907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1557275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":45,"alternative-id":["10.3389\/fchem.2025.1557275"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2025.1557275","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1557275"}}